A study has shown that GDC-0077, a small-molecule inhibitor targeting the PI3K signaling pathway that can be used for the treatment of patients with PIK3CA-mutant breast cancer, is currently in phase III clinical trials [262]. Here, PIK3CA is linked to breast carcinoma.